10th Jun 2022 14:42
Syncona Ltd - London-based investor in healthcare companies - Announces that its portfolio company, Autolus Therapeutics PLC, has published new clinical data across multiple programmes. Autolus reports "positive" early safety and efficacy data from Auto4 in patients with T cell lymphoma and "encouraging" early safety and efficacy data from Auto1/22 in paediatric acute lymphoblastic leukaemia.
Current stock price: 196.00 pence, down 0.5% in London on Friday
12-month change: down 7.3%
By Heather Rydings; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Syncona